Abstract: A wire-feeding electromagnetic spray additive manufacturing device and method are provided. The device includes a housing, an alternating current power box is fixedly installed on the housing, and a stirring needle is also arranged in the housing. The device further includes a fixed seat fixedly installed in the housing, and a heating coil is arranged between the fixed seat and the stirring needle; a lower end of the stirring needle is provided with spinnerets and heating channels adapted with corresponding the spinnerets respectively; upper ends of the heating channels penetrate through the stirring needle and are fixedly connected with the housing, and an extrusion assembly is fixedly installed on each of the heating channels; and a smoke pipe is fixedly installed on the extrusion assembly, and an upper end of the smoke pipe penetrates through the housing and is connected with a negative pressure fan.

Abstract: A manufacturing method of amorphous nanocrystalline composite materials includes following steps: S1, transferring raw materials through a feeding mechanism; S2, generating metal droplets from the raw materials under an action of one of an electric spark and an electric arc through a pulse power supply; S3, transporting the metal droplets below a flying plate under an action of a transmission medium; S4, generating a magnetic field force through electromagnetic pulse coils disposed on the flying plate to drive the flying plate to impact the metal droplets onto surfaces of substrates; S5, repeating the S1 to S4, thereby forming dense amorphous nanocrystalline composite materials. The pulse power supply is utilized to generate the metal droplets from the raw materials under the action of the electric spark or the short electric arc, and then the metal droplets are formed to the dense amorphous nanocrystalline composite materials.

Abstract: A method containing a compound as shown in formula 1, or a pharmaceutically acceptable salt, prodrug, isotopic variant or solvate thereof in preparation of a medicament: The medicament is suitable for preventing, relieving, and/or treating skin diseases or disorders associated with anti-tumor agents in a subject. Also disclosed is a method for treating skin diseases or disorders associated with anti-tumor agents by the compound.

Abstract: A method for treating chemotherapy-related gastrointestinal side effects, in particular, relating to use of a CDK inhibitor in preparation of a drug. The drug is used for preventing, alleviating and/or treating the chemotherapy-related gastrointestinal side effects on a subject. The CDK inhibitor comprises a CDK1 inhibitor, a CDK2 inhibitor, a CDK3 inhibitor, a CDK4 inhibitor, a CDK5 inhibitor, a CDK6 inhibitor, a CDK7 inhibitor, a CDK 8 inhibitor, and/or CDK9 inhibitor. A chemotherapeutic agent may be selected from fluorouracil, oxaliplatin, topotecan, irinotecan, tetrahydrofolate, docetaxel, and the like. The gastrointestinal side effects comprise diarrhea, constipation, and the like.

Abstract: A compound and method may treat chemotherapy-associated gastrointestinal side effects. A compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament: may be used for preventing, alleviating, and/or treating gastrointestinal side effects associated with chemotherapy in a subject. A method may use such a compound to treat chemotherapy-associated gastrointestinal side effects.

Abstract: A charger including a vertical section including a first surface, the first surface facing a front direction and including an attachment portion configured to a receive a battery pack, and a horizontal section configured to protrude, in the front direction, from a bottom portion of the vertical section. The charger further including a second surface disposed on the horizontal section, the second surface facing an upward direction, and a fan disposed proximate the horizontal surface, the fan configured to cool the battery pack.

Abstract: A charger including a vertical section including a first surface, the first surface facing a front direction and including an attachment portion configured to a receive a battery pack, and a horizontal section configured to protrude, in the front direction, from a bottom portion of the vertical section. The charger further including a second surface disposed on the horizontal section, the second surface facing an upward direction, and a fan disposed proximate the horizontal surface, the fan configured to cool the battery pack.

Abstract: A JAK inhibitor may be used in preparation of a medicament. The medicament may be used for preventing and/or treating a disease or condition associated with an antitumor agent in a subject. A pharmaceutical composition may include the JAK inhibitor as may a kit. The JAK inhibitor may include a compound of formula (I) or a pharmaceutically acceptable salt thereof: Q, X, Y, and Z being independently N or C, and R1, R2 and R3 being independently a 5-6-membered aromatic ring, 5-6-membered heteroaromatic ring, 5-6-membered cycloalkyl, 5-6-membered heterocycloalkyl, amino, or amido, the aromatic ring, heteroaromatic ring, cycloalkyl, and/or heterocycloalkyl being optionally substituted by a substituent.

Abstract: A flexible adaptive large length to thin ratio pipeline intelligent repair device is provided. The walking mechanism includes a walking bracket and a radius adjustment assembly. The radius adjustment assembly is located in the middle of the walking bracket. The first motor for driving the radius adjustment assembly is set in the middle of the walking mechanism, and the second motor for driving the movement of the walking bracket is set on the walking bracket. The ends of several groups of connecting rods are removably connected to the working part, which includes the pre-welding sandblasting mechanism, the heating mechanism and the welding repair mechanism. A positioning sensor is set on the walking bracket. The variable-diameter all-position intelligent pipe internal repair device can integrate pre-welding cleaning, preheating, welding repair and post-welding heat treatment.

Abstract: The present application relates to a thymidine derivative, or use of a uridine derivative in combination with a thymidine derivative in preparation of a drug for preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject. The present application further provides a method of preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject comprising administering a prophylactically or therapeutically effective amount of a thymidine derivative or uridine and thymidine derivatives to a subject in need thereof.

Abstract: A power margin tracking control method and system for a multi-terminal high-voltage direct current converter station are provided. A power adjustment factor is introduced on the basis of a droop coefficient, to realize a self-adaptive regulation of a converter station operation mode to a real-time fluctuation of a wind and solar power. In this way, the system operation stability and the power fluctuation allocation capability in a grid-connected system are improved. Furthermore, a DC voltage deviation in the multi-terminal high-voltage direct current grid is reduced.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

Abstract: The present disclosure relates to colloids comprising caffeine-tannic acid complexes which slow the release of the caffeine. Also described are methods of preparing the colloids and beverages comprising colloids comprising caffeine-tannic acid complexes.

Abstract: A method for treating or preventing saccharide-related diseases or disorders, comprising administering a therapeutically or prophylactically effective amount of a polymer comprising at least one boronic acid group to a subject having or at risk of having a saccharide-related disease or disorder.

Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.